| Item Type | Name |
|
Concept
|
Piperidines
|
|
Academic Article
|
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
|
|
Academic Article
|
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
|
|
Academic Article
|
Three-year follow-up of treatment-na?ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
|
|
Academic Article
|
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
|
|
Academic Article
|
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
|
|
Academic Article
|
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
|
|
Academic Article
|
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
|
|
Academic Article
|
Ibrutinib: a paradigm shift in management of CLL.
|
|
Academic Article
|
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
|
|
Academic Article
|
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.
|
|
Academic Article
|
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
|
|
Academic Article
|
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
|
|
Academic Article
|
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
|
|
Academic Article
|
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
|
|
Academic Article
|
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
|
|
Academic Article
|
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.
|
|
Academic Article
|
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
|
|
Academic Article
|
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
|
|
Academic Article
|
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
|
|
Academic Article
|
?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.
|
|
Academic Article
|
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
|
|
Academic Article
|
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
|
|
Academic Article
|
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
|
|
Academic Article
|
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
|
|
Academic Article
|
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
|
|
Academic Article
|
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
|
|
Academic Article
|
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
|
|
Academic Article
|
Single-agent ibrutinib in treatment-na?ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
|
|
Academic Article
|
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic?leukaemia treated with ibrutinib from 3 clinical trials.
|
|
Academic Article
|
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
|
|
Academic Article
|
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
|
|
Academic Article
|
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
|
|
Academic Article
|
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
|
|
Academic Article
|
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
|
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
|
|
Academic Article
|
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
|
|
Academic Article
|
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
|
|
Academic Article
|
Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
|
|
Academic Article
|
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.
|
|
Academic Article
|
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
|
|
Academic Article
|
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
|
|
Academic Article
|
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
|
|
Academic Article
|
Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations.
|
|
Academic Article
|
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
|
|
Academic Article
|
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
|
|
Academic Article
|
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
|
|
Academic Article
|
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
|